TAFRO syndrome associated with C3 nephropathy (an analysis of clinical experience)
https://doi.org/10.17650/1818-8338-2023-17-3-K697
Abstract
Aim. To present a clinical case of TAFRO syndrome – a recently described subtype of idiopathic multicentric Castleman disease of unknown etiology, characterized by thrombocytopenia, anasarca, fever, reticulin fibrosis of the bone marrow and / or renal dysfunction, organomegaly associated with an increase in serum IL-6 secretion.
Materials and methods. Herein, we report a young patient diagnosed with TAFRO combined with C3 nephropathy. The patient was treated with glucocorticoids (methylprednisolone), colchicine, sarilumab, rivaroxaban, and symptomatic treatment.
Results. Key aspects of diagnosis, treatment and course of the syndrome were discussed. The possibility of the combined course of two rare pathologies – a subtype of idiopathic multicentric Castleman disease and C3 nephropathy is still unclear.
Conclusion. The diagnosis of TAFRO syndrome can be considered after the exclusion of a number of infectious, paraneoplastic, systemic connective tissue diseases, POEMS syndrome, liver cirrhosis against the background of autoimmune hepatitis, autoimmune thrombocytopenic purpura, as well as hemolytic-uremic syndrome. Kidney damage in this category of patients, in most of the described clinical cases, is morphologically represented by thrombotic microangiopathy or mesangioproliferative glomerulonephritis. C3 nephropathy in that clinical case seems to be concomitant. Glucocorticoids in high and ultrahigh doses, cyclosporine, IL-6 type inhibitors, as well as anti-CD20 antibodies are used as therapy.
About the Authors
I. V. Pozharov
M. F. Vladimirsky Moscow Regional Scientific Research Clinical Institute (MONIKI); N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
61 / 2 Shchepkina St., Moscow 129110
1 Ostrovityanov St., Moscow 117997
A. O. Grigorevskaya
M. F. Vladimirsky Moscow Regional Scientific Research Clinical Institute (MONIKI)
Russian Federation
Russian Federation
61 / 2 Shchepkina St., Moscow 129110
G. R. Setdikova
M. F. Vladimirsky Moscow Regional Scientific Research Clinical Institute (MONIKI)
Russian Federation
Russian Federation
61 / 2 Shchepkina St., Moscow 129110
E. S. Stolyarevich
Intercircular Nephrological Center of the Moscow “City Clinical Hospital No. 52 of the Moscow Department of Health”
Russian Federation
Russian Federation
52, 3 / 2 Pekhotnaya St., Moscow 123182
References
1. Castleman B., Iverson L., Menendez V.Р. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 1956;9(4):822–30. DOI: 10.1002/1097-0142(195607/08)9: 4<822::aid-cncr2820090430>3.0.co;2–4
2. Dispenzieri A., Armitage J.O., Loe M.J. et al. The clinical spectrum of Castleman’s disease. Am J Hematol 2012;87(11):997–1002. DOI: 10.1002/ajh.23291
3. Neipel F., Albrecht J.C., Ensser A. et al. Human herpesvirus 8 encodes a homolog of interleukin-6. J Virol 1997;71(1):839–42. DOI: 10.1128/JVI.71.1.839-842.1997
4. Suthaus J., Stuhlmann-Laeisz C., Tompkins V.S. et al. HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. Blood 2012;119(22):5173–81. DOI: 10.1182/blood-2011-09-377705
5. Cronin D.M., Warnke R.A. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol 2009;16(4):236–46. DOI: 10.1097/PAP.0b013e3181a9d4d3
6. Takai K., Nikkuni K., Shibuya H., Hashidate H. Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly. Rinsho Ketsueki 2010;51(5):320–25. PMID: 20534952
7. Masaki Y., Kawabata H., Takai K. et al. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol 2016;103(6): 686–92. DOI: 10.1007/s12185-016-1979-1
8. Masaki Y., Kawabata H., Takai K. et al. 2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol 2020;111(1):155–8. DOI: 10.1007/s12185-019-02780-1
9. Leurs A., Gnemmi V., Lionet A. et al. Renal pathologic findings in TAFRO syndrome: Is there a continuum between thrombotic microangiopathy and membranoproliferative glomerulonephritis? A case report and literature review. Front Immunol 2019;10:1489. DOI: 10.3389/fimmu.2019.01489
10. Iwaki N., Fajgenbaum D.C., Nabel C.S. et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol 2016;91(2):220–6. DOI: 10.1002/ajh.24242
11. Tu K.H., Fan P.Y., Chen T.D. et al. TAFRO syndrome with renal thrombotic microangiopathy: Insights into the molecular mechanism and treatment opportunities. Int J Mol Sci 2021;22(12):6286. DOI: 10.3390/ijms22126286
12. Nagayama Y., Yamano M., Yagame M. et al. TAFRO syndrome as a cause of glomerular microangiopathy: A case report and literature review. BMC Nephrol 2019;20(1):375. DOI: 10.1186/s12882-019-1574-9
13. Ravindran A., Fervenza F.C., Smith R.J.H. et al. C3 glomerulopathy: Ten years’ experience at Mayo Clinic. Mayo Clin Proc 2018;93(8):991–1008. DOI: 10.1016/j.mayocp.2018.05.019
14. Igawa T., Sato Y. TAFRO syndrome. Hematol Oncol Clin North Am 2018;32(1):107–18. DOI: 10.1016/j.hoc.2017.09.009
15. Akiyama M., Kaneko Y., Takeuchi T. Tocilizumab for the treatment of TAFRO syndrome: A systematic literature review. Ann Hematol 2020;99(11):2463–75. DOI: 10.1007/s00277-020-04275-0
16. Jain P., Verstovsek S., Loghavi S. et al. Durable remission with rituximab in a patient with an unusual variant of Castleman’s disease with myelofibrosis-TAFRO syndrome. Am J Hematol 2015;90(11):1091–2. DOI: 10.1002/ajh.24015
17. Ide M., Kawachi Y., Izumi Y. et al. Long-term remission in HIV-negative patients with multicentric Castleman’s disease using rituximab. Eur J Haematol 2006;76(2):119–23. DOI: 10.1111/j.1600-0609.2005.00570.x
Review
For citations:
Pozharov I.V., Grigorevskaya A.O., Setdikova G.R., Stolyarevich E.S. TAFRO syndrome associated with C3 nephropathy (an analysis of clinical experience). The Clinician. 2023;17(3):42-49. (In Russ.) https://doi.org/10.17650/1818-8338-2023-17-3-K697
Views:
489
Email this article 